NBE Therapeutics AG

Ipsen SA has resumed its oncology shopping spree and moved into the antibody-drug conjugate (ADC) space for the first time by linking up with Sutro Biopharma, Inc. of the US. The French mid-sized p

The hot area of antibody-drug conjugates (ADCs) is getting a new player with the launch of Pheon Therapeutics , a UK-based biotech that comes armed with a sizeable cash pile and a hugely experienced

Although family-owned Boehringer Ingelheim GmbH is the only private firm in the top 20 largest biopharmas, its executives are quick to explain that most of their operations function in the same way

Danish biotech ADCendo ApS believes it can create a pipeline of antibody-drug conjugates targeting the novel cancer target uPARAP, bringing a lead candidate into clinical trials probably by 2023 usi